ATE539763T1 - Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit - Google Patents

Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit

Info

Publication number
ATE539763T1
ATE539763T1 AT06780613T AT06780613T ATE539763T1 AT E539763 T1 ATE539763 T1 AT E539763T1 AT 06780613 T AT06780613 T AT 06780613T AT 06780613 T AT06780613 T AT 06780613T AT E539763 T1 ATE539763 T1 AT E539763T1
Authority
AT
Austria
Prior art keywords
disease
parkinson
alzheimer
growth factor
nervous system
Prior art date
Application number
AT06780613T
Other languages
English (en)
Inventor
Alessandro Lambiase
Stefano Bonini
Original Assignee
Anabasis S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anabasis S R L filed Critical Anabasis S R L
Application granted granted Critical
Publication of ATE539763T1 publication Critical patent/ATE539763T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06780613T 2005-08-19 2006-08-11 Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit ATE539763T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000447A ITRM20050447A1 (it) 2005-08-19 2005-08-19 Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
PCT/IT2006/000620 WO2007020672A2 (en) 2005-08-19 2006-08-11 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease

Publications (1)

Publication Number Publication Date
ATE539763T1 true ATE539763T1 (de) 2012-01-15

Family

ID=37667295

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06780613T ATE539763T1 (de) 2005-08-19 2006-08-11 Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit

Country Status (11)

Country Link
US (1) US20090118177A1 (de)
EP (1) EP1948217B1 (de)
JP (1) JP2009504724A (de)
AT (1) ATE539763T1 (de)
CA (1) CA2619721A1 (de)
DK (1) DK1948217T3 (de)
ES (1) ES2376992T3 (de)
IL (1) IL189605A (de)
IT (1) ITRM20050447A1 (de)
RU (1) RU2429007C2 (de)
WO (1) WO2007020672A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827210B2 (en) * 2007-06-29 2017-11-28 Phovitreal Pty Ltd Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration
CN101972224B (zh) * 2010-09-13 2012-01-04 舒泰神（北京）生物制药股份有限公司 一种眼用原位凝胶
IT202000032423A1 (it) 2020-12-24 2022-06-24 Univ Degli Studi Di Trieste Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959319A (en) * 1985-08-01 1990-09-25 Skelnik Debra L Process of corneal enhancement
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6063757A (en) * 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
IT1283911B1 (it) * 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
BR9712824A (pt) * 1996-09-13 1999-12-21 Advanced Medicine Research Ins Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico
IT1291892B1 (it) * 1997-04-24 1999-01-21 Alessandro Lambiase Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella
WO2000007613A1 (fr) * 1998-08-05 2000-02-17 Advanced Medicine Research Institute Remedes contenant des facteurs neurotrophiques pour le traitement des lesions cerebrales centrales
JP2002531490A (ja) * 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系に薬剤を投与するための方法
IT1305294B1 (it) * 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US20020009498A1 (en) * 1999-11-05 2002-01-24 Guy L. Clifton Methods and compositions for treatment of traumatic brain injury
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing

Also Published As

Publication number Publication date
CA2619721A1 (en) 2007-02-22
IL189605A (en) 2013-10-31
WO2007020672A3 (en) 2007-05-31
US20090118177A1 (en) 2009-05-07
ES2376992T3 (es) 2012-03-21
RU2429007C2 (ru) 2011-09-20
IL189605A0 (en) 2008-06-05
ITRM20050447A1 (it) 2007-02-20
EP1948217B1 (de) 2012-01-04
RU2008110505A (ru) 2009-09-27
WO2007020672A2 (en) 2007-02-22
JP2009504724A (ja) 2009-02-05
EP1948217A2 (de) 2008-07-30
DK1948217T3 (da) 2012-02-20

Similar Documents

Publication Publication Date Title
Stein et al. Beta oscillations in the cortico-basal ganglia loop during parkinsonism
Fisher et al. AF150 (S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer’s disease
WO2012006419A3 (en) Pro-neurogenic compounds
Wang et al. Therapeutic strategies for Parkinson’s disease: the ancient meets the future—traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells
MX2012010657A (es) Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
Petrovic et al. Lesion of the pedunculopontine tegmental nucleus in rat augments cortical activation and disturbs sleep/wake state transitions structure
BR112015020391A2 (pt) gama-dicetonas como ativadoras da via de sinalização de wnt/beta-catenina
Liu et al. Effect of oral administration of Pheretima aspergillum (earthworm) in rats with cerebral infarction induced by middle-cerebral artery occlusion
Nam et al. Acupuncture stimulation induces neurogenesis in adult brain
BR112015004942A2 (pt) benzimidazóis como agentes ativos do snc
Krystal et al. EEG correlates of the response to ECT: a possible antidepressant role of brain-derived neurotrophic factor
ATE539763T1 (de) Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit
Billeri et al. A narrative review on non-invasive stimulation of the cerebellum in neurological diseases
Petrovic et al. REM sleep diversity following the pedunculopontine tegmental nucleus lesion in rat
Alosaimi et al. The role of neurotransmitter systems in mediating deep brain stimulation effects in Parkinson’s disease
Jaseja Meditation may predispose to epilepsy: an insight into the alteration in brain environment induced by meditation
Cavalli et al. Role of acupuncture in the management of severe acquired brain injuries (sABIs)
Povarnina et al. Dimeric dipeptide mimetics of NGF and BDNF are promising agents for post-stroke therapy
Calne Parkinsonism: Clinical and neuropharmacologic aspects
Huang et al. 2017 yearbook of neurorestoratology
Jiao Embryonic and adult neural stem cell research in China
BR112015008200A2 (pt) derivados de imidazopiridina
Gao et al. Roles of p75NTR in maintaining brain hemostasis and the implications for p75NTR-targeted therapies
Bernert et al. Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome
Agnesi et al. Brain Stimulation: Chapter 4. Deep brain stimulation: how does it work?